Intended for UK patients and members of the public
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintProduct Documentation
Last updated on this site: 09 Aug 2023
Update section 4.2, 4.3, 4.6, 4.8, 4.9, and 5.1 of SmPC and section 1, 2, 3 and 4 of PIL information in line with the information of Reference product (AMARYL 1 mg, 2 mg, 3 mg, 4 mg.
Last updated on this site: 06 Nov 2025
Type IA (B.II.b.2.a) To add Labanalysis Life Science S.r.l. Via Europa 5, Casanova Lonati, 27041, Italy as an alternative site responsible for batch control/testing of the finished product.
Type IAIN (B.II.b.1.a): To add Accord Healthcare single member S.A., 64th Km National Road Athens, Lamia, Schimatari, 32009, Greece as an alternative site responsible for secondary packaging of the finished product.
Type IAIN (B.II.b.2.C.2): To add Accord Healthcare single member S.A., 64th Km National Road Athens, Lamia, Schimatari, 32009, Greece as an alternative site responsible for importation and batch release including batch control/testing of the finished product.
Consequently, the PIL is updated.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk. By reporting side effects, you can help provide more information on the safety of this medicine.
Report a side effect or a product complaintFor any further assistance, please get in touch.